Sobi will showcase extensive research and clinical outcomes at ISTH 2025
"Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions", said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
"We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions."
Data to be presented at ISTH 2025
ALTUVOCT® (efanesoctocog alfa)
OC 64.4: Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program
Presenting author: Liane Khoo
Oral presentation
Session date: Tuesday 24 June
Session time: 14:45 - 16:00 EDT
Location: 151 A&B, Walter E. Washington CC Convention Center
OC 20.5: Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis
Presenting author: Lynn Malec
Oral presentation
Session date: Sunday 22 June
Session time: 14:45 - 16:00 EDT
Location: Ballroom A-C, Walter E. Washington CC Convention Center
PB0847: Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program
Presenting author: Pratima Chowdary
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB1425: Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed
Presenting author: Christoph Königs
Poster presentation
Session date: Tuesday 24 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
General Haemophilia
PB0778: Addressing unmet medical needs and health inequities in haemophilia A: expertconsensus statements
Presenting author: Cédric Hermans
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB0816: Extravascular distribution of factor IX: evidence and relevance for haemophilia B replacement therapy
Presenting author: Cédric Hermans
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB1439: Monitoring Joint Health in Haemophilia Patients in Spain: Updated Analysis of the JOIN-US Project
Presenting author: María Teresa Álvarez Román
Poster presentation
Session date: Tuesday 24 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
ALPROLIX® (rFIXFc)
PB0868: Real-World Effectiveness and Usage
of Recombinant Factor IX Fc: Final Data from the B-MORE Study
Presenting author: Heidi Glosli
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Doptelet® (avatrombopag)
PB0348: Consistent Response to Avatrombopag for the Treatment of Children with ITP Across Various Baseline Characteristics
Presenting author: Rachael F. Grace
Poster presentation
Session date: Sunday 22 June
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
PB0364: Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration
Presenting author: Rachael F. Grace
Poster presentation
Session date: Sunday 22 June
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
OC 65.3: Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure
Presenting author: Srikanth Nagalla
Oral presentation
Session date: Tuesday 24 June 2025
Session time: 14:45 – 16:00 EDT
(Presentation time currently in programme: 15:15 – 15:30 EDT)
All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later.
About ALTUVOCT® (efanesoctocog alfa)
ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity.
About Elocta®/Eloctate® (efmoroctocog alfa)
Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups.
About Alprolix® (eftrenonacog alfa)
Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups.
About Doptelet® (avatrombopag)
Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About the Sanofi and Sobi collaboration
Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025,c4166601
The following files are available for download:
https://mb.cision.com/Main/14266/4166601/3514826.pdf
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
View original content:https://www.prnewswire.co.uk/news-releases/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025-302486857.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Afternoon napping could have surprising impact on longevity, study suggests
A new study linking daytime napping to increased mortality rates in older adults may have some rethinking that midday snooze. The study, presented last month at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies in Seattle, Washington, found that frequent, longer and irregular daytime naps — especially in the early afternoon — were linked to a higher risk of death over an eight-year period. "Our study fills a gap in knowledge," lead author Chenlu Gao, a postdoctoral research fellow at Massachusetts General Hospital in Boston, told Fox News Digital. Study Reveals Exercising Every Day May Not Be Necessary: 'Better Than None' The research shows "not just whether someone naps, but how long, how variable, and when they nap during the day may be meaningful indicators of future health risk," he said. The study included 86,565 participants averaging 63 years of age — all of whom worked regular daytime schedules — who were monitored by actigraphy, which detects movement during sleep but not brain activity. Read On The Fox News App Scientists defined daytime napping as sleeping between 9 a.m. and 7 p.m. After the initial study, researchers kept tabs on the participants for eight years and discovered that 5,189 (6.0%) of them died during that time period. Most Americans Hit The Snooze Button Every Morning — Here's Why It Could Be Bad For Your Health The research showed that taking longer naps — and napping between 11 a.m. and 1 p.m. or between 1 p.m. and 3 p.m. — was associated with a higher mortality rate. Results were adjusted for other potential factors influencing mortality, like demographics, weight, smoking, alcohol consumption and nighttime sleep duration, the researchers stated. "Naps are not necessarily problematic unless they are used to compensate for chronically poor sleep at night," Dr. Chelsie Rohrscheib, a neuroscientist and sleep specialist at Wesper in New York, told Fox News Digital. "Getting seven to nine hours of good quality sleep is required to maintain health and reduce the risk of developing dangerous medical conditions like heart disease and diabetes," added Rohrscheib, who was not involved in the study. The study did not establish proof that naps directly affect the risk of death. "These are associations," Gao told Fox News Digital. "We cannot conclude from this study whether napping causes poor health." Most Sleep-deprived Cities In Us Revealed In Report: Where Does Yours Rank? In another potential limitation, because the study relied on detecting movement but not brain activity, "quiet wakefulness" may have been misclassified as sleep. Additionally, defining daytime napping as sleep between 9 a.m. and 7 p.m. could have mistakenly included participants' actual sleep, affecting the accuracy of what would count as a nap, the researchers stated. Excessive napping could also be a marker of other health issues, such as chronic disease, systemic inflammation, or disruptions to circadian rhythms, which may themselves increase mortality risk. "Someone who requires daily naps to get through the day is likely not getting sufficient sleep during the night, or has an underlying health condition that causes daytime sleepiness," Rohrscheib noted. Gao added, "We need more research to understand the causal relationships before we can conclude that a certain type of napping pattern would benefit health." "However, we suggest that monitoring napping patterns might help us identify health conditions early, so that we can implement interventions accordingly." The American Academy of Sleep Medicine encourages healthy adults to limit naps to no longer than 20 to 30 minutes in the early afternoon. Click Here To Sign Up For Our Health Newsletter While a brief "power nap" can improve daytime alertness and performance, naps of 30 minutes or longer may cause a person to feel groggy after waking up. This grogginess, or "sleep inertia," can delay the short-term benefits of a nap, experts say. For more Health articles, visit Overall, the findings suggest that when it comes to mid-day snoozing, moderation is key — and that napping patterns could be a window into broader health concerns worth discussing with a medical article source: Afternoon napping could have surprising impact on longevity, study suggests
Yahoo
2 hours ago
- Yahoo
NASA to Launch New Livestream Service on Netflix Starting This Summer
NASA to Launch New Livestream Service on Netflix Starting This Summer originally appeared on L.A. Mag. NASA+ will offer live programming of rocket launches, astronaut spacewalks, mission coverage, and live views of Earth from the International Space Station through its new streaming platform on Netflix. 'The National Aeronautics and Space Act of 1958 calls on us to share our story of space exploration with the broadest possible audience,' Rebecca Sirmons, general manager of NASA+ at the agency's headquarters in Washington said. 'Together, we're committed to a Golden Age of Innovation and Exploration – inspiring new generations – right from the comfort of their couch or in the palm of their hand from their phone.'NASA+ first launched in 2023 to make space content more accessible to the public. The service will continue to be available for free and ad-free through the NASA app and website. NASA wrote that they hope to bring even more awareness to their work through Netflix's global audience of more than 700 million people. 'Through this partnership, NASA's work in science and exploration will become even more accessible, allowing the agency to increase engagement with and inspire a global audience in a modern media landscape,' Cheryl Warner, NASA news chief, wrote in a press schedules will drop closer to launch day, so Netflix advises viewers to check for more details in the coming weeks. This story was originally reported by L.A. Mag on Jul 1, 2025, where it first appeared.
Yahoo
2 hours ago
- Yahoo
Washington, Oregon sue Trump admin for sharing Medicaid files with immigration enforcement
Washington's Nick Brown is among the state attorneys general suing over the U.S. Department of Health and Human Services for sharing Medicaid patients' files with the Department of Homeland Security. (Photo by Ryan Berry/Washington state Standard) Washington and Oregon's attorneys general are suing the federal government for sharing residents' Medicaid records with federal immigration enforcement officials. Oregon Attorney General Dan Rayfield and Washington Attorney General Nick Brown, alongside 13 other Democratic state attorneys general, filed a lawsuit on Tuesday challenging the U.S. Department of Health and Human Services for sharing Medicaid patients' files with the Department of Homeland Security, where Immigration and Customs Enforcement, or ICE, is housed. The Health and Human Services Department, it's secretary, Robert F. Kennedy Jr., and the Homeland Security Department and it's secretary, Kristi Noem, are listed as defendants. California Attorney General Rob Bonta is leading the lawsuit, which also includes the attorneys general of Arizona, Colorado, Connecticut, Delaware, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York and Rhode Island. The state attorneys argue that sharing personal health data violates federal administrative procedure laws and federal privacy laws. States are asking the court to block any new transfer of data, and the use of any data currently held by Homeland Security and ICE for immigration enforcement purposes. Since Congress established Medicaid seven decades ago, 'federal law, policy, and practice has been clear: the personal healthcare data collected about beneficiaries of the program is confidential,' officials from Brown's office said in a news release. On June 13, the state attorneys general learned through news reports that officials at the Health and Human Services Department transferred Medicaid data files to ICE officials. Those reports indicate that the federal government plans to create a database for mass deportations and other large-scale immigration enforcement purposes, Brown said in a news release. 'Washington residents expect that the confidential information they give to the government to access medical treatment will only be used for healthcare purposes,' Brown said in a news release. 'Their data should not go towards creating a giant database of Americans' personal information or used so that ICE can deport undocumented immigrants because they had to go to the doctor.' Oregon and Washington are among seven states that offer Medicaid to eligible adults regardless of immigration status, and are among 14 states, plus Washington, D.C., that cover children regardless of immigration status. Oregon has 100,000 people enrolled in its 'Healthier Oregon' program, a state-funded program which provides access to Medicaid coverage regardless of immigration status, according to the Oregon Health Authority. About 49,000 people of the nearly 2 million people in Washington who rely on the state's Medicaid Program Apple Health have an immigration status that makes them ineligible for federal funding. 'This has a chilling impact on people who need healthcare in our country,' Rayfield said in the news release. 'Parents may choose not to take their kids to the doctor because they're afraid of what may happen. We need to protect the privacy and dignity of every person who calls Oregon home.' UPDATED at 5:50 p.m. with information from the filed lawsuit and a link to the lawsuit. This article was first published by the Oregon Capital Chronicle, part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity. Oregon Capital Chronicle maintains editorial independence. Contact Editor Julia Shumway for questions: info@
